Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Tysabri is a medicine for treating adults with multiple sclerosis (MS) that is not sufficiently controlled with another disease-modifying therapy or is rapidly getting worse.
Multiple sclerosis is a disease of the nerves, in which inflammation destroys the protective sheath surrounding nerves and damages the nerves themselves.
Tysabri is used in relapsing-remitting MS, a type of MS in which the patient has attacks (relapses) between periods of stable symptoms (remissions).
It contains the active substance natalizumab.
Expand section
Collapse section
How is Tysabri used?
Treatment with Tysabri should be started and supervised by a doctor who is experienced in treating diseases of the nervous system and has access to a magnetic resonance imaging (MRI) scanner. This scanner will enable the doctor to check for changes in the brain or spinal cord linked to MS or to the brain infection called progressive multifocal leukoencephalopathy (PML), which has been associated with Tysabri and other MS medicines.
Tysabri is given as a 1-hour infusion (drip) into a vein once every 4 weeks. Because the infusion can trigger an allergic reaction, the patient must be monitored during the infusion and for 1 hour afterwards. If there is no clear benefit for the patient after 6 months, the doctor should re-assess the treatment.
The medicine can only be obtained with a prescription.
For more information about using Tysabri, see the package leaflet or contact your doctor or pharmacist.
How does Tysabri work?
The active substance in Tysabri, natalizumab, is a monoclonal antibody which targets a protein called ?4?1 integrin on white blood cells involved in inflammation. By attaching to integrin, natalizumab is thought to stop white blood cells from entering the brain and spinal cord tissue, thereby reducing inflammation and the resulting nerve damage. This helps to reduce symptoms of the disease.
What benefits of Tysabri have been shown in studies?
Tysabri was effective at reducing the number of relapses and the worsening of disability (as measured with the Expanded Disability Status Scale).
In a study comparing Tysabri with placebo (a dummy treatment), the number of MS attacks in Tysabri-treated patients fell by about 68% after a year, compared with the patients who received placebo. In addition, the risk of disability getting worse was reduced by 42% over 2 years with Tysabri in comparison with placebo.
A second study showed that adding Tysabri to treatment with another medicine, interferon beta-1a, was more effective than adding placebo, reducing the risk of disability getting worse and the number of relapses. While the study showed that Tysabri was effective, it also raised concerns that combination with interferon beta-1a increased the risk of the serious brain infection PML.
Finally, a third study, still ongoing, has shown the average number of MS attacks per year falling from about 2 to 0.2 in Tysabri-treated patients (regardless of which disease-modifying treatment they had previously used). The response was maintained for up to 5 years.
What are the risks associated with Tysabri?
Tysabri can increase the risk of infections, including the brain infection PML. PML is a very serious condition that may result in severe disability or death. The risk of PML increases the longer a patient has been receiving Tysabri, especially in patients treated for more than 2 years. The risk is also higher for patients who used medicines that supress the immune system before starting Tysabri, or if the patient has antibodies against the virus that causes PML. If PML is suspected, the doctor must stop treatment until it is certain that the patient does not have the infection.
The most common side effects with Tysabri (which may affect more than 1 in 10 people) are urinary tract infection, nasopharyngitis (inflammation of the nose and throat), headache, dizziness, nausea (feeling sick), joint pain and tiredness.
About 6% of the patients in studies developed long-lasting antibodies against natalizumab, which reduced the medicine’s effectiveness.
Tysabri must not be given to patients who have PML or who are at risk of getting an infection, including patients whose immune system is weakened. It must not be given in combination with other disease-modifying medicines or to patients who have cancer (unless it is a skin cancer called basal cell carcinoma).
For the full list of side effects and restrictions of Tysabri, see the package leaflet.
Why is Tysabri authorised in the EU?
Studies have shown that Tysabri is effective in treating relapsing-remitting MS. However, because of its safety risks, it should only be used in patients who have a real need for the medicine either because their disease is not sufficiently controlled with at least one other disease-modifying therapy or is rapidly getting worse.
The European Medicines Agency decided therefore that Tysabri’s benefits are greater than its risks and it can be authorised for use in the EU.
What measures are being taken to ensure the safe and effective use of Tysabri?
The company that markets Tysabri has agreed on measures to improve the monitoring of patients with each Member State, such as registries and studies of patients receiving Tysabri. It will also supply all doctors who prescribe Tysabri with an educational pack that includes information on the safety of Tysabri, including information on which patients may be at a higher or lower risk of PML. Patients should receive this information when starting Tysabri, when continuing treatment for longer than 2 years, and when stopping treatment, as the risk of PML persists for 6 months after stopping treatment. The pack will also include information about other risks of this medicine for patients.
Patients who receive Tysabri must be given a special alert card that summarises the key safety information about the medicine. Patients should read this card carefully and keep it with them. Patients should make sure their partner or carer, as well as other doctors treating them, are aware of its content.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tysabri have also been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Tysabri are continuously monitored. Side effects reported with Tysabri are carefully evaluated and any necessary action taken to protect patients.
Other information about Tysabri
Tysabri received a marketing authorisation valid throughout the EU on 27 June 2006.
Tysabri : EPAR - Medicine overview
English (EN) (135.59 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
Other languages (22)
български (BG) (148.94 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
español (ES) (130.78 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
čeština (CS) (147.56 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
dansk (DA) (130.28 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
Deutsch (DE) (133.77 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
eesti keel (ET) (132.58 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
ελληνικά (EL) (149.91 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
français (FR) (134.51 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
hrvatski (HR) (147.14 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
italiano (IT) (130.35 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
latviešu valoda (LV) (121.13 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
lietuvių kalba (LT) (146.69 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
magyar (HU) (147.68 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
Malti (MT) (122.33 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
Nederlands (NL) (129.83 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
polski (PL) (148.2 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
português (PT) (130.87 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
română (RO) (144.96 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
slovenčina (SK) (147.74 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
slovenščina (SL) (145.89 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
Suomi (FI) (127.34 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
svenska (SV) (129.65 KB - PDF)
First published:
18/06/2009
Last updated:
04/05/2020
View
Tysabri : EPAR - Risk-management-plan
English (EN) (614.01 KB - PDF)
First published:
21/02/2024
Last updated:
26/05/2026
View
Product information
Tysabri : EPAR - Product information
English (EN) (1.62 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
Other languages (24)
български (BG) (1.53 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
español (ES) (1.67 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
čeština (CS) (1.78 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
dansk (DA) (1.67 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
Deutsch (DE) (1.7 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
eesti keel (ET) (1.72 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
ελληνικά (EL) (1.54 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
français (FR) (1.74 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
hrvatski (HR) (1.85 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
íslenska (IS) (1.68 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
italiano (IT) (1.35 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
latviešu valoda (LV) (1.79 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
lietuvių kalba (LT) (1.4 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
magyar (HU) (1.42 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
Malti (MT) (1.95 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
Nederlands (NL) (1.67 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
norsk (NO) (1.64 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
polski (PL) (1.78 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
português (PT) (1.34 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
română (RO) (1.8 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
slovenčina (SK) (1.8 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
slovenščina (SL) (1.79 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
Suomi (FI) (1.69 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
svenska (SV) (1.28 MB - PDF)
First published:
18/06/2009
Last updated:
26/05/2026
View
Latest procedure affecting product information:
VR/0000315289
10/04/2026
This medicine’s product information is available in all official EU languages. Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Tysabri : EPAR - All authorised presentations
English (EN) (43.43 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
Other languages (24)
български (BG) (86.54 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
español (ES) (79.66 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
čeština (CS) (83.3 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
dansk (DA) (86.62 KB - PDF)
First published:
09/11/2007
Last updated:
23/01/2026
View
Deutsch (DE) (81.56 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
eesti keel (ET) (76.48 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
ελληνικά (EL) (82.76 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
français (FR) (61.54 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
hrvatski (HR) (81.43 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
íslenska (IS) (45.07 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
italiano (IT) (78.32 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
latviešu valoda (LV) (82.65 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
lietuvių kalba (LT) (82.78 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
magyar (HU) (81.54 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
Malti (MT) (83.71 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
Nederlands (NL) (61.14 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
norsk (NO) (80.71 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
polski (PL) (47.38 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
português (PT) (81.08 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
română (RO) (81.14 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
slovenčina (SK) (83.54 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
slovenščina (SL) (79.13 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
Suomi (FI) (76.81 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
svenska (SV) (79.35 KB - PDF)
First published:
09/11/2007
Last updated:
09/01/2026
View
Tysabri : EPAR - Conditions imposed on member states for safe and effective use - Annex IV
English (EN) (43.8 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
Other languages (23)
български (BG) (146.24 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
español (ES) (94.75 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
čeština (CS) (129.15 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
dansk (DA) (97.4 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
Deutsch (DE) (34.99 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
eesti keel (ET) (33.93 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
ελληνικά (EL) (201.72 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
français (FR) (32.69 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
íslenska (IS) (62.24 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
italiano (IT) (34.25 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
latviešu valoda (LV) (126.71 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
lietuvių kalba (LT) (132.36 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
magyar (HU) (97.93 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
Malti (MT) (130.18 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
Nederlands (NL) (26.05 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
norsk (NO) (36.75 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
polski (PL) (134.09 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
português (PT) (34.82 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
română (RO) (130.19 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
slovenčina (SK) (134.95 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
slovenščina (SL) (163.84 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
Suomi (FI) (95.74 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
svenska (SV) (94.46 KB - PDF)
First published:
31/05/2007
Last updated:
08/07/2011
View
Product details
Name of medicine
Tysabri
Active substance
natalizumab
International non-proprietary name (INN) or common name
natalizumab
Therapeutic area (MeSH)
Multiple Sclerosis
Anatomical therapeutic chemical (ATC) code
L04AG03
Pharmacotherapeutic group
Monoclonal antibodies
Therapeutic indication
Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:
- Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1) or
- Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.
Authorisation details
EMA product number
EMEA/H/C/000603
Marketing authorisation holder
Biogen Netherlands B.V.
Prins Mauritslaan 13 1171 LP Badhoevedorp The Netherlands
Marketing authorisation issued
27/06/2006
Revision
52
Assessment history
Expand section
Collapse section
Changes since initial authorisation of medicine
Tysabri : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (194.37 KB - PDF)
First published:
14/11/2025
Last updated:
26/05/2026
View
Tysabri : EPAR - Procedural steps taken and scientific information after authorisation (archive)
English (EN) (411.46 KB - PDF)
First published:
18/06/2009
Last updated:
14/11/2025
View
Tysabri-H-C-PSUSA-00002127-202108 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Reference Number:
EMA/561269/2022
English (EN) (126.92 KB - PDF)
First published:
08/06/2022
View
Tysabri-H-C-PSUSA-00002127-202008 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Reference Number:
EMA/158932/2021
English (EN) (96.16 KB - PDF)
First published:
15/06/2021
View
Tysabri-H-C-603-X-0116 : EPAR - Assessment report - Extension
Adopted
Reference Number:
EMA/CHMP/102816/2021
English (EN) (1.71 MB - PDF)
First published:
06/04/2021
View
CHMP post-authorisation summary of positive opinion for Tysabri (X-116)
Adopted
Reference Number:
EMA/CHMP/50871/2021
English (EN) (131.35 KB - PDF)
First published:
01/02/2021
View
Tysabri-H-C-PSUSA-00002127-201908 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Reference Number:
EMA/160227/2020
English (EN) (132.93 KB - PDF)
First published:
04/05/2020
View
Tysabri-H-C-603-II-77 : EPAR - Assessment Report - Variation
Adopted
Reference Number:
EMA/579064/2016
English (EN) (2.48 MB - PDF)
First published:
07/09/2016
Last updated:
07/09/2016
View
CHMP post-authorisation summary of positive opinion for Tysabri
Adopted
Reference Number:
EMA/CHMP/181854/2016
English (EN) (121.79 KB - PDF)
First published:
27/05/2016
Last updated:
27/05/2016
View
Tysabri : EPAR - Scientific Conclusion
English (EN) (72.27 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
Other languages (22)
български (BG) (100.06 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
español (ES) (73.9 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
čeština (CS) (93.86 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
dansk (DA) (72.2 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
Deutsch (DE) (70.07 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
eesti keel (ET) (69.43 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
ελληνικά (EL) (119.04 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
français (FR) (72.68 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
hrvatski (HR) (109.16 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
italiano (IT) (69.5 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
latviešu valoda (LV) (112.38 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
lietuvių kalba (LT) (109.25 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
magyar (HU) (93.66 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
Malti (MT) (119.22 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
Nederlands (NL) (70.67 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
polski (PL) (98.26 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
português (PT) (74.99 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
română (RO) (130.53 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
slovenčina (SK) (93.91 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
slovenščina (SL) (91.56 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
Suomi (FI) (66.64 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
svenska (SV) (70.69 KB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
Tysabri-H-C-603-A20-1416 : EPAR - Assessment Report - Article 20
Adopted
Reference Number:
EMA/PRAC/171485/2016
English (EN) (1.4 MB - PDF)
First published:
12/05/2016
Last updated:
12/05/2016
View
Tysabri-H-C-603-PSUV-0062 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
Reference Number:
EMA/178698/2014
English (EN) (72.55 KB - PDF)
First published:
01/04/2014
Last updated:
01/04/2014
View
Tysabri-H-C-603-II-0059-G : EPAR - Assessment Report - Variation
Adopted
Reference Number:
EMA/297726/2013
English (EN) (738.39 KB - PDF)
First published:
20/08/2013
Last updated:
20/08/2013
View
CHMP post-authorisation summary of positive opinion for Tysabri
Reference Number:
EMA/321062/2013
English (EN) (68.45 KB - PDF)
First published:
31/05/2013
Last updated:
31/05/2013
View
Tysabri-H-C-603-A20-0029: EPAR - Assessment Report - Article 20
Adopted
Reference Number:
EMA/430923/2010
English (EN) (114.16 KB - PDF)
First published:
19/08/2010
Last updated:
19/08/2010
View
Initial marketing authorisation documents
Tysabri : EPAR - Scientific Discussion
English (EN) (243.79 KB - PDF)
First published:
31/05/2007
Last updated:
31/05/2007
View
Tysabri : EPAR - Procedural steps taken before authorisation
English (EN) (198.25 KB - PDF)
First published:
31/05/2007
Last updated:
04/05/2020
View
News on Tysabri
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021
29/01/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 May 2016
27/05/2016
EMA confirms recommendations to minimise risk of brain infection PML with Tysabri
26/02/2016
Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri
12/02/2016
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 May 2015
08/05/2015
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013
31/05/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 18-21 January 2010
28/01/2010
European Medicines Agency recommends additional measures to better manage risk of progressive multifocal leukoencephalopathy (PML) with Tysabri
21/01/2010
European Medicines Agency recommends update of product information of Tysabri and risk of progressive multifocal leukoencephalopathy (PML)
25/09/2008
European Medicines Agency update on progressive multifocal leukoencephalopathy (PML) and Tysabri
13/08/2008
European Medicines Agency concludes new advice to doctors and patients for Tysabri (natalizumab) needed
20/03/2008
Product information - with tracked changes
The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.
Tysabri : EPAR – Product information – tracked changes
English (EN) (1.35 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
Other languages (24)
български (BG) (926.43 KB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
español (ES) (1.34 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
čeština (CS) (1.35 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
dansk (DA) (1.31 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
Deutsch (DE) (1.35 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
eesti keel (ET) (1.36 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
ελληνικά (EL) (1.37 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
français (FR) (1.34 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
hrvatski (HR) (1.31 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
íslenska (IS) (1.38 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
italiano (IT) (835.71 KB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
latviešu valoda (LV) (1.36 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
lietuvių kalba (LT) (812.89 KB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
magyar (HU) (821.45 KB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
Malti (MT) (1.35 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
Nederlands (NL) (1.32 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
norsk (NO) (1.33 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
polski (PL) (1.34 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
português (PT) (839.24 KB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
română (RO) (1.32 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
slovenčina (SK) (1.36 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
slovenščina (SL) (1.31 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
Suomi (FI) (1.32 MB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
svenska (SV) (797.41 KB - DOCX)
First published:
19/06/2025
Last updated:
09/01/2026
View
More information on Tysabri
Questions and answers on the review of Tysabri (natalizumab)
Reference Number:
EMA/27573/2010
English (EN) (65.06 KB - PDF)
First published:
21/01/2010
Last updated:
21/01/2010
View
More information on Tysabri
- EMEA-001095-PIP02-12 - paediatric investigation plan
- Tysabri - withdrawal of application for variation to marketing authorisation
- Tysabri - referral
- EMEA-001095-PIP03-19 - paediatric investigation plan
- An observational study utilising data from the US Tysabri TOUCH programme and select EU MS Registries to estimate the risk of progressive multifocal leukoencephalopathy (PML) and other serious opportunistic infections among patients who were exposed to an MS disease modifying treatment prior to treatment with Tysabri - post-authorisation study
- An Observational Study Utilising Data from EU National MS Registries to Estimate the Incidence of Anti-Natalizumab Antibody Among Patients Who Receive Subcutaneous Administration of Natalizumab for Treatment of RRMS - post-authorisation study
- TOP: Tysabri® Observational Program - post-authorisation study
- An Observational, Cross-Sectional Survey to Assess PML Risk Awareness and Understanding from Patients’ Perspective and Effectiveness of the Tysabri (Natalizumab) Patient Alert Card in the UK (T-PAC) - post-authorisation study
Topics
This page was last updated on
26/05/2026
Summary
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised